Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Insel Gruppe AG, University Hospital Bern
With
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) who are managed at home or in another out-of-hospital setting.
You may not be if
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including Child-Pugh C cirrhosis with portal hypertension.
Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Uncontrolled severe hypertension.
Ongoing or planned treatment with parenteral or oral anticoagulants
Unilateral or bilateral above knee lower extremity amputation.
Inability to take oral medication or otherwise unable or unwilling to undergo/perform study-specified procedures
Have received or will receive an experimental drug or used an experimental medical device within 30 days before the planned start of treatment
Pregnancy or breast-feeding or any plan to become pregnant during the study. Women (and men, for Colchicine group only) with child-bearing potential not using adequate birth control method (note: as adequate method of birth control oral contraception is recommended. If oral contraception is not feasible, both partners should use adequate barrier birth control).
Need for dual anti-platelet therapy consisting of aspirin and an oral P2Y12 inhibitor
Inflammatory bowel disease or chronic diarrhea or neuromuscular disease
Creatinine clearance (CrCl) \<15 ml/min
Anticipated use of Hydroxychloroquine
Participation in any other clinical trial
Inability to understand the requirements of the study and to provide informed consent
Clareo Health | CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
